Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
flucloxacillin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving flucloxacillin 250 mg | EXPERIMENTAL | Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose |
| Subjects receiving flucloxacillin 500 mg | EXPERIMENTAL | Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose |
| Name | Type | Description |
|---|---|---|
| flucloxacillin 250 mg | DRUG | Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose |
| flucloxacillin 500 mg | DRUG | Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose |
Inclusion Criteria: * Healthy volunteers, * Caucasians, * Body Mass Index (BMI) between 19 and 27 kg/m 2; * physically and mentally healthy as judged by means of a medical and standard lab examination; * non-smokers, * ex-smokers or moderate smoker. Exclusion criteria: * medical history, * vital ...
Flucloxacillin is a small molecule antibiotic used for bacterial infections. It is being developed by GSK plc for the treatment of infections caused by susceptible bacteria. The drug is currently in Phase 1 clinical development, meaning it is still investigational and has not yet been approved for commercial use.
Flucloxacillin is developed by GSK plc, a global pharmaceutical company traded on the New York Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's bioavailability and pharmacokinetic profile in healthy volunteers.
Flucloxacillin is in Phase 1 clinical development. A Phase 1 trial has been completed to assess the bioavailability of flucloxacillin capsules at 250 mg and 500 mg doses. The drug remains investigational and has not received regulatory approval for any indication.
Flucloxacillin has one completed Phase 1 clinical trial registered under NCT00358371, titled "Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)". This randomized, controlled study enrolled 24 participants in Germany to evaluate the drug's bioavailability in healthy volunteers aged 18 years and older.
Flucloxacillin is a distinct antibiotic compound developed by GSK plc. It belongs to the penicillin class of antibiotics and is specifically designed to treat bacterial infections. No alternative names for this drug have been established in the clinical development program.